Evidence
Payer and provider-related value demonstration: HEOR, RWE, and budget-impact modeling built around what committees weigh, sequenced ahead of the asks.
40%+
typical gross-to-net erosion on major US brands
Half
to two-thirds of launches fail to meet expectations
3 audiences
payers, providers, and patients: value must resonate with all three
The leak is quiet and expensive. The dossier focuses on endpoints and clinical value, while payers ask about budget impact and providers ask about net cost recovery. Contracts offered discounts for desired access and restriction positions, but formulary decision-makers thought otherwise. Rebates and/or discounts stack. The field never follows up on where access was achieved, so wins that were bought never get pulled through.
Pricing compounds it. Launch prices are set on thin competitive intelligence. Gross to net grows while access does not improve. Indegene prepares for all of this, so pricing is set purposefully, taking into account manufacturers' goals, and the value is maximized.
Value dossiers built on trial endpoints alone are losing to budget-impact and real-world outcome evidence designed around what committees actually weigh. HEOR moves upstream into development.
Contracting needs to support outcome-based agreements and indication-specific pricing. Value-based constructs are moving from press release to practice. Teams that can model and negotiate secure access that flat rebates cannot buy.
The price set today must understand tomorrow's policy environment. IRA negotiations and MFP, PBM FTC/CAA reform, MFN, GENEROUS, GUARD/GLOBE and international reference pricing, and 340B rebate pilots take center stage.
Access wins realize value only when field, marketing, and patient services activate them. The organizations connecting coverage data to engagement in days collect what others leave on the table.
Every shift rewards the same thing: access run as a continuous value-realization system. We run it from evidence planning and generation to communication. We run it from evidence planning, generation to communication.
Payer and provider-related value demonstration: HEOR, RWE, and budget-impact modeling built around what committees weigh, sequenced ahead of the asks.
Insights from this stage can then inform the next cycle of evidence planning and negotiation.
Explore how multi-country payer insights helped a biopharma company refine pricing strategy, strengthen product positioning, and improve margins.
Explore how public drug pricing could reshape market access, gross-to-net strategy, and global pricing decisions.
Explore payer perspectives on how the Most Favored Nation policy could influence drug pricing, market access, and affordability across global markets.
Budget-impact models, RWE studies, and payer-relevant value dossiers.
Launch pricing, international sequencing, and continuous gross-to-net management.
Account strategy, negotiation support, and value communication.
Outcome-based agreement design, modeling, and operations.
Live coverage tracking, restriction analysis, and opportunity mapping on Komodo patient-level claims.
Coverage wins pushed to field, marketing, and patient services in days.
Value realization is the full chain from evidence to collected net revenue: payer-relevant proof, pricing, contracting, and pull-through.
Indegene runs it as one continuous system, ending the era of the launch-time dossier.
Erosion slows when pricing is governed continuously, contracts are modeled before they are signed, and every rebate has an owner and a return.
Indegene runs gross-to-net as a live discipline.
Payers weigh budget impact, real-world outcomes, and comparative value in their populations.
Indegene builds HEOR and RWE programs around those questions, sequenced ahead of negotiations.
Consultancies deliver the strategy and depart.
Indegene runs the system: evidence, pricing governance, contracting operations, and pull-through activation, with fees tied to realized outcomes.
Bring us your access plan and gross-to-net picture. Within 3 weeks, you will have a value leak analysis, a realization roadmap, and committed access milestones.
Get the value leak diagnostic.